Denosumab may lower risk of type 2 diabetes in adults with osteoporosis
China: A new study published in the BMJ: British Medical Journal suggests that denosumab, a medication used to treat osteoporosis, may have an added benefit for glucose metabolism compared with oral bisphosphonates.
The study aimed to assess the effect of denosumab versus oral bisphosphonates on the risk of type 2 diabetes in persons with osteoporosis.
The study involved the emulation of a randomized target trial using electronic health records. The study analyzed 4301 new users of denosumab from the IQVIA Medical Research Data primary care database in the United Kingdom from 1995 to 2021.
The participants included were adults aged 45 and over who were using denosumab or an oral bisphosphonate for osteoporosis. The main outcome was the occurrence of type 2 diabetes, as determined by diagnostic codes.
The study revealed the following clinical takeaways:
1. The incidence rate of type 2 diabetes in denosumab users was 5.7 per 1000 person-years.
2. The incidence rate of type 2 diabetes in oral bisphosphonate users was 8.3 per 1000 person-years.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.